ArticleEndocrine-related cancer2026
Intraprostatic steroid hormones and endocrine disruptors in prostate cancer.
Article in Endocrine-related cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate cancer (PCa) is a hormone-dependent malignancy governed by steroid signaling. Despite characterization of androgen pathways, the broader intraprostatic steroid environment remains underexplored. Endocrine-disrupting chemicals (EDCs) may modulate these processes, yet their tissue distribution is largely unknown. We aimed to comprehensively profile intraprostatic steroids and EDCs and assess their associations with tumor aggressiveness, prognosis, and risk stratification. Thirty steroids and 16 EDCs were quantified using liquid chromatography-tandem mass spectrometry in cancerous tissue, non-cancerous tissues (from peripheral and transition zones), and plasma from 173 patients with localized PCa undergoing robot-assisted radical prostatectomy. Analysis of variance was used to compare analyte levels across biological matrices and according to disease aggressiveness, multivariate statistical models evaluated associations with patient prognosis and risk categories, and machine learning (ML) models were applied for risk stratification. Steroid profiles differed markedly between plasma and prostate tissue, whereas EDCs accumulated in the prostate and were generally not associated with plasma concentrations. Cancerous tissue showed lower conjugated dehydroepiandrosterone (DHEA) and higher pregnenolone, corticoids, and testosterone compared to non-cancerous tissue. Elevated intratumoral cortisol, cortisone, androstenedione, conjugated testosterone, 7-ketoDHEA, and estrone were associated with greater tumor aggressiveness. Higher intratumoral parabens correlated with increased postoperative PSA, while conjugated dihydrotestosterone (DHT) and phytoestrogen daidzein were inversely associated with PSA levels. Higher EDC burden and intratumoral steroid levels were associated with higher risk categories. In contrast, DHT showed a consistent protective profile, being negatively associated with both prognosis and risk classification. Integrating steroids and EDCs improved ML-based risk classification beyond preoperative clinical variables.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.